Press Release | Newsroom | Medtronic | Medtronic Converts 125 Million Patient Days of Data Into Personalized Insights That Improve Diabetes Management

Press Release

Printer Friendly Version View printer-friendly version
Download PDF Download PDF
<< Back
Medtronic Converts 125 Million Patient Days of Data Into Personalized Insights That Improve Diabetes Management

CareLink® Portfolio Updates, IBM Watson Partnership Progress and New Strategic Alliances Delivering Intelligent Data and Actionable Information at ADA 2016

DUBLIN and NEW ORLEANS - June 10, 2016 - Delivering on its vision to transform care for the millions currently living with diabetes through intelligent data, Medtronic plc (NYSE:MDT) announced new product developments and technology partnerships at the American Diabetes Association (ADA) 76th Scientific Sessions that will create meaningful insights for providers and people with diabetes.

New CareLink® offerings and advancement of the Medtronic partnership with IBM Watson Health give doctors and their patients more actionable information, enabling care that is more collaborative, consistent and effective. In addition, the growing network of Medtronic partnerships combines Medtronic diabetes expertise with capabilities expanding data usefulness to provide more holistic diabetes solutions.

"Data, insights and analytics have been a cornerstone for our diabetes strategy with CareLink, and we have accumulated over 125 million patient days of data generated by our devices, including continuous glucose monitoring (CGM) sensor readings and insulin pump events," said Annette Brüls, president, Diabetes Service and Solutions at Medtronic. "Through our advanced CareLink portfolio and our expanded network of partnerships, we present actionable insights to drive holistic diabetes care solutions that offer greater freedom and better health to people with diabetes."

Medtronic is introducing several breakthrough solutions to improve and simplify diabetes management. These solutions include a combination of CareLink advancements, data from Medtronic devices and analytical capabilities of IBM Watson Health as well as an expanded network of partners such as Nutrino and Glooko.

CareLink Software - Delivering More Information to Physicians and Their Patients
Medtronic continues to expand its CareLink portfolio, helping physicians make confident treatment decisions and patients understand more about managing their diabetes effectively.  CareLink Pro software, available for over a decade, is the highest rated diabetes therapy management tool by healthcare professionals.

  • CareLink Pro Reports Now Available to Patients: People with diabetes now have access to seven current CareLink Pro reports through CareLink Personal software, helping them have more productive discussions with their doctors. When patients and their doctors can view the same reports, diabetes care becomes more collaborative and the information in the reports becomes more actionable. Through Medtronic informatics and data analysis, CareLink reports will continue to provide diabetes patients with useful insights that can facilitate productive conversations about treatment options and provide a big-picture perspective on an individual's patterns and trends.
  • New CareLink Pro Reports: Showing for the first time at ADA, CareLink Pro software will reveal four new reports that allow physicians to optimize patient treatment. Through advanced informatics and analysis of glycemic patterns, bolus behavior and basal rates, doctors can enhance insulin pump therapy effectiveness, reduce burden and improve overall care.  Available later this summer, these reports will offer doctors new insights on key diabetes management challenges.

IBM Watson Health - Advancing Our Partnership
Medtronic, along with its strategic technology partner IBM Watson Health, have advanced to the final development stages of a first-of-its-kind cognitive app. The Medtronic app is designed to assist people in making daily diabetes management easier and potentially more effective.The first generation of the Medtronic app is expected to detect important patterns and trends - based on retrospective analysis of patients' insulin, CGM and nutritional data - to help people understand how their behavior affects their glucose level in real time. In addition to further advance the capabilities of future generations of the app, the companies have revealed new results on hypoglycemia prediction using CareLink data from 10,000 anonymized patients which demonstrated preliminary prediction accuracy of 75%-86% within a two-to-four hour window1.

Nutrino - Data Partnership Lets MiniMed® Connect Users See the Impact of Food on Diabetes
Medtronic has also entered into a data partnership with Nutrino, a technology-based platform focused on diet and nutrition. MiniMed Connect customers will now have access to a new Nutrino app that combines CGM data with Nutrino's science-based nutritional insights. The new app, currently in beta testing, will use Nutrino's proprietary technology to give users a FoodPrint(TM) based on their daily food intake, activity, sleep and other parameters affecting their glucose levels.

Glooko - First Mobile Health Solution Compatible with Medtronic Pumps and Sensors
Glooko, a unified platform for diabetes management, now has compatibility with Medtronic insulin pumps and sensors. This integration gives Medtronic customers expanded options for displaying and using their diabetes data. Glooko's integrated solution optimizes workflows for both people with diabetes and clinics to download data from Medtronic. As a part of the 'Glooko Advise' decision support product line, Glooko also has the ability to correlate insulin data with readings and biometrics data collected from over 50 blood glucose meters and fitness devices. They will demonstrate their integration at the ADA in booth 811.

About the Diabetes Group at Medtronic (
Medtronic is working together with the global community to change the way people manage diabetes. The company aims to transform diabetes care by expanding access, integrating care and improving outcomes, so people living with diabetes can enjoy greater freedom and better health.

About Medtronic
Medtronic plc (, headquartered in Dublin, Ireland, is among the world's largest medical technology, services and solutions companies - alleviating pain, restoring health and extending life for millions of people around the world. Medtronic employs more than 85,000 people worldwide, serving physicians, hospitals and patients in approximately 160 countries. The company is focused on collaborating with stakeholders around the world to take healthcare Further, Together.

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.


1 Preliminary research results - based on dataset in controlled environment - Data on File


Pamela Reese
Public Relations

Ryan Weispfenning
Investor Relations